 
 
 
Date: July 31, 2025 
 
To, 
Listing Department,  
National Stock Exchange of India Limited 
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, 
Bandra (E), Mumbai – 400051 
 
NSE Symbol: BALAXI 
 
Subject:  Business Responsibility and Sustainability Report for FY 2024-25 
 
Dear Sir/Madam, 
 
Please find enclosed the Business Responsibility and Sustainability Report (“BRSR”) of 
Balaxi Pharmaceuticals Limited (“the Company”) for Financial Year 2024-25. BRSR forms 
part of the Annual Report 2024-25 of the Company. 
 
The BRSR along with the Annual Report 2024-25 is available on the website of the Company 
at:  
 
https://balaxipharma.in/assets/images/articles/AR_2024-25.pdf 
 
This is submitted pursuant to Regulation 34(2) of the SEBI (Listing Obligations and 
Disclosure Requirements) Regulations, 2015. 
 
This is for your information and records. 
 
Yours Faithfully, 
For Balaxi Pharmaceuticals Limited 
 
 
Mohith Kumar Khandelwal 
(Company Secretary & Compliance Officer) 
Membership No.: F11243 
 
Encl: A/a 
 
 
 
MOHITH KUMAR 
KHANDELWAL
Digitally signed by MOHITH 
KUMAR KHANDELWAL 
Date: 2025.07.31 16:54:35 +05'30'
Section A) General Disclosures 
I. 
Details of the listed entity
1.
2.
3.
Year of incorporation
1942
4.
Registered office address
rd Floor, 
500096
5.
Corporate address
rd Floor, 
500096
6.
secretarial@balaxi.in
7.
Telephone
8.
Website
www.balaxipharma.in
9.
Financial year for which reporting is being done
10.
11.
12.
Mr.Mohith Kumar Khandelwal, Company Secretary 
13.
basis (i.e. for the entity and all the entities which form a part of its 
The disclosure under this report are made on a 
Standalone basis.
14.
Name of the assurance provider
Not Applicable 
15.
Type of assurance obtained
Not Applicable 
II. 
Product & Services
S No
Description of Main Activity 
Description of Business Activity 
% of turnover of the entity 
1
Trading
International Wholesale trading/distribution
100%
S No
Product /Service
NIC Code 
% of the total turnover contributed 
1
Pharmaceutical Products
464
100.00
III.  
Operations 
18.  Number of locations where plants an/or operations/offices of the entity are situated 
Location 
Number of Plants 
Number of Offices 
Total 
National
1 *
1
2
International 
Business Responsibility & 
Sustainability Report
87
Corporate Overview
Statutory Reports
Financial Statements
Corporate Identity Number (CIN) of the Listed Entity 
Name of the Listed Entity 
E-mail 
Name of the Stock Exchange(s) where shares are listed 
Paid-up Capital 
Name and contact details (telephone, email address) of the person 
L25191TG1942PLC121598 
BALAXI PHARMACEUTICALS LIMITED 
PLOT No.409,H.No:8-2-293, Maps Towers,3 
Phase-Ill, Road No.81,Jubilee Hills, Hyderabad (T.G.)-
PLOT No.409,H.No:8-2-293, Maps Towers,3 
Phase-Ill, Road No.81,Jubilee Hills, Hyderabad (T.G.)-
+9140 23555300 
April 2024- March 2025 
National Stock Exchange of India Limited 
11,04,15,000 (Eleven Crores Four Lakhs and Fifteen 
Thousand Only) 
who may be contacted in case of any queries on the BRSR report: and 
Compliance 
Officer, 
Telephone: 
+9140 
23555300, Email: secretarial@balaxi.in 
Reporting boundary - Are the disclosures under this report made 
on a standalone basis (i.e. only for the entity) or on a consolidated 
consolidated financial statements, taken together): 
16. 
Details of business activities (accounting for 90% of the turnover): 
17. 
Products/Services sold by the entity (accounting for 90% of the entity's turnover) 
* Manufacturing plant to be launched in Hl FY26: 
Locations 
Number 
0
8
b.  
What is the contribution of exports as a percentage of the total turnover of the entity ? 100%
IV.  
Employees 
20. 
Details at the end of Financial Year
SL 
No.
Particulars 
Total (A)
Male
Female 
No.(B)
%(B/A)
No.(C)
%(C/A)
Employees 
1
48
43
89.58
5
10.42
2
-
-
-
-
-
3
Total Employees
48
43
89.58
5
10.42
Workers 
4
5
6
 
Instruction /Guidance 
SL 
No.
Particulars 
Total (A)
Male
Female 
No. ( B)
% ( B/A)
No. (C)
% ( C/A)
Differently Abled Employees 
1
2
3
Differently Abled Workers 
4
5
6
21.  Participation/Inclusion/Representation of Women 
Particulars 
Total (A)
No. and percentage of Females 
No.(B)
% ( B/A)
Board of directors
6
2
33.33
Key Management Personnel
4
0
0
Balaxi Pharmaceuticals Limited - 
88
Annual Report FY24-25 
19. 
Markets served by the entity: 
a. 
Number of Locations 
National (No. of States) 
International (No. of Countries) 
c. 
A brief on types of customers : Distributors, Wholesalers and Retailers 
a. 
Employees and workers (including differently abled): 
Permanent(D) 
·--------·--------------------------------------------------------------------------·--------------------------------------------------------------------
Other than permanent(E) 
(D+E) 
Permanent(F) 
Other than permanent(G) 
·--------·--------------------------------------------------------------------------·--------------------------------------------------------------------
Tota I Employees(F+G) 
20.b Differently Abled Employees & Workers 
Permanent(D) 
Other than permanent(E) 
Total Employees(D+E) 
Permanent(F) 
Other than permanent(G) 
Total Employees(F+G) 
Turnover Rate-FY2025
Turnover Rate-FY2024
Turnover Rate-FY2023
Male 
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
15 %
42.86%
20.45%
39%
33%
30.43%
17.5%
30%
20%
Permanent Workers
S. 
No.
Name of the holding / subsidiary 
/ associate companies / joint 
ventures (A)
Indicate whether holding/ 
Subsidiary/ Associate/ 
Joint Venture
% of shares 
held by listed 
entity
Does the entity 
indicated at column 
A, participate in the 
Business Responsibility 
initiatives of the listed 
entity? 
(Yes/Nom)
1
Holding Company
Not Applicable
No
2
Balaxi Global DMCC, Dubai
Wholly owned subsidiary
100%
No
3
Balaxi Healthcare Ecuador
Wholly owned subsidiary
100%
No
4
Balaxi Healthcare Guatemala, S.A, 
Republic of Guatemala
subsidiary
100%
No
5
Balaxi Healthcare Dominicana, 
subsidiary
100%
No
6
Balaxi Healthcare Honduras, S.DE 
subsidiary
100%
No
7
Balaxi Healthcare Centrafrique, 
subsidiary
100%
No
8
Balaxi Healthcare El Salvador S.A 
DE., El Salvador
subsidiary
100%
No
9
Balaxi Healthcare Angola, Republic 
of Angola
subsidiary
100%
No
subsidiaries.
Company
VI. 
CSR Details 
24. 
89
Corporate Overview
Statutory Reports
Financial Statements
22. 
Turnover rate for permanent employees and workers. 
(Disclose trends for the past 3 years) ---
23. (a) Names of holding/subsidiary/associate companies/joint ventures 
Balaxi Overseas Private Limited 
Wholly owned Step-down 
Wholly owned Step-down 
S.R.L, Dominican Republic 
Wholly owned Step-down 
R.L.DE C.V Honduras 
Wholly owned Step-down 
SARL, Centrafrique 
Wholly owned Step-down 
Wholly owned Step-down 
Note: Balaxi Global DMCC, Dubai, Wholly Owned Subsidiary of the Company holds 100% of shares in the step-down 
Balaxi Overseas Private Limited is Holding of the Company and it holds 63.40 % of the total equity Shares of the 
(i) 
Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) :Yes 
(ii) 
Turnover (in Rs.) 6,098.82 Lakhs 
(iii) 
Net worth (in Rs.):12,785.27 Lakhs 
VII. Transparency and Disclosures Compliances 
Stakeholder 
Group from 
whom 
complaint is 
received 
Grievance Redressal 
Mechanism in Place.
Yes/No (If Yes, then 
provide web-link for 
grievance 
redress 
policy)
FY 2025
FY 2024
Number of 
complaints 
filed during 
the year 
Number of 
complaints 
pending 
resolution 
at close of 
the year 
Remarks 
Number of 
complaints 
filed during 
the year 
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks 
Communities 
Yes
Nil
Nil
Nil
Nil
Investors 
(Other than 
Yes
Nil
Nil
Nil
Nil
Shareholders
Yes
Nil
Nil
Nil
Nil
Yes
Nil
Nil
Nil
Nil
Customers 
Yes
Nil
Nil
Nil
Nil
Value Chain 
Partners 
Yes
Nil
Nil
Nil
Nil
Other (Please 
26.  Overview of the entity’s material responsible business conduct issues 
 
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 
SL 
No
Material Issue 
Identified 
Indicate 
whether Risk 
/ Opportunity 
(R/O)
Rational for identifying 
risk or opportunity 
In case of risk, 
approach to adapt or 
mitigate 
Financial implication 
of risk or opportunity 
(Indicate positive or 
negative implications) 
1
Carbon 
Footprint in 
Global Supply 
Chain
Climate change will result 
in stricter environmental 
regulations 
across 
sectors, this will increase 
transportation cost for the 
Company.
Ensuring 
Vendors/
CDMOs 
are 
in 
compliance 
with 
the 
applicable 
e n v i r o n m e n t a l 
standards.
operating 
costs 
in 
meeting 
the 
environmental standards.
2
Diversity and 
Inclusion
Opportunity
Foster 
a 
diverse 
and 
that promotes equality, 
equal opportunities for all 
employees. this will lead 
to a good talent pool for 
the company 
productivity will increase 
environment
Balaxi Pharmaceuticals Limited - 
90
Annual Report FY24-25 
25. 
Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business 
Conduct: 
https://balaxipharma. 
in/corporate-policies 
https://balaxipharma. 
-~-~~~~~-~~~-~~~~-- _in/ corporate-po Ii ci es ---------------------------------------------------- --------------------------------------------------
Employees & 
Workers 
https://balaxipharma. 
in/corporate-policies 
https://balaxipharma. 
in/corporate-policies 
https://balaxipharma. 
·--------------------·-in/ corporate-po Ii ci es ----------------------------------------------------·--------------------------------------------------
https://balaxipharma. 
·--------------------·-in/ corporate-po Ii ci es ----------------------------------------------------·--------------------------------------------------
specify) 
matters that present a risk or an opportunity to your business, the rationale for identifying the same, approach to adapt 
or mitigate the risk along with its financial implications, as per the following format 
Risk 
Negative: 
Increased 
Positive implication: the 
inclusive 
workplaces 
due to healthy work 
non-discrimination, 
and 
SL 
No
Material Issue 
Identified 
Indicate 
whether Risk 
/ Opportunity 
(R/O)
Rational for identifying 
risk or opportunity 
In case of risk, 
approach to adapt or 
mitigate 
Financial implication 
of risk or opportunity 
(Indicate positive or 
negative implications) 
3
Corporate 
Governance
Opportunity
Ensuring 
a 
good 
governance 
and 
transparent practices can 
interest, 
a 
higher 
and improved financial 
performance.
transparent practices
SECTION B: Management and Process Disclosures
This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the 
NGRBC Principles and Core Elements.
Disclosure Questions 
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and Management Processes 
1. a. Whether your entity’s policy/policies cover each 
principle and its core elements of the NGRBCs. (Yes/
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
b. 
Has the policy been approved by the Board? 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
2. 
Whether the entity has translated the policy into 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
3. 
Do the enlisted policies extend to your value chain 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
4. 
Name of the national and international codes/
certifications/labels/ standards (e.g. Forest Stewardship 
your entity and mapped to each principle.
None
5. 
Specific commitments, goals and targets set by the 
entity with defined timelines, if any.
The Company is determined to follow the path envisioned under 
the 9 principles laid down in the National Voluntary Guidelines 
Business issued by the Ministry of Corporate Affairs
6. 
Performance of the entity against the specific 
case the same are not met.
The Company shall continue to monitor its performance 
when the need arises
Governance, leadership and oversight
7. 
Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets 
8. 
Details of the highest authority responsible for 
implementation and oversight of the Business 
9. 
Does the entity have a specified Committee of the 
 
If yes, details. 
Yes, the Committee consists of Managing Director as 
Chairman along with other functional heads.
91
Corporate Overview
Statutory Reports
Financial Statements
Positive 
implication: 
Reduced 
risk 
due to 
help securing stakeholder 
reputation, reduced risks, 
No) 
(Yes/No) 
c. 
Web Link of the Policies, if available 
https://balaxipharma.in-policies 
·-------------------------------------------------------------------------------·---------------------------------------------------------------------------------
procedures. (Yes/ No) 
partners? (Yes/No) 
Council, 
Fairtrade, 
Rainforest 
Alliance, 
Trustea) 
standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by 
on Social, Environmental & Economic Responsibilities of 
commitments, goals and targets along-with reasons in against the said principle(s) and take necessary action as and 
and achievements (listed entity has flexibility regarding the placement of this disclosure) 
The purpose of our business is to dedicatedly serve to ensure stakeholder delight and influence the environment and 
society at large with our good work, as we abide by our values that form the cornerstone of our business strategies, 
decisions, and activities. We are committed to this roadmap as we seek to grow sustainably and deliver Pharmaceutical 
Products to frontier markets with excellence, again and again, with a lot more rigor and enthusiasm as the days pass. 
·-------------------------------------------------------------------------------·---------------------------------------------------------------------------------
Responsibility policy (ies). 
Board/ Director responsible for decision making on 
sustainability related issues? (Yes / No). 
Mr.Ash ish Maheshwari (DIN:01575984), Managing Director 
Telephone:+9140 23555300 
Email:secretarial@balaxi.in 
Subject for Review 
Indicate whether review was undertaken 
by Director / Committee of the Board/ 
Any other Committee
Frequency (Annually/ Half yearly/ 
Quarterly/ Any other – please specify)
P1
P2
P3
P4
P5
P6
P7
P8
P9
P1
P2
P3
P4
P5
P6
P7
P8
P9
Performance against above policies 
and follow up action
Y
Y
Y
Y
Y
Y
Y
Y
Y
Half Yearly
Compliance 
with 
statutory 
requirements of relevance to the 
principles, and, rectification of any 
Y
Y
Y
Y
Y
Y
Y
Y
Y
Quarterly
11.  Has the entity carried out independent assessment/ evaluation of the 
the agency.
P1
P2
P3
P4
P5
P6
P7
P8
P9
N
N
N
N
N
N
N
N
N
Questions 
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the Principles material to its business 
NA
NA
NA
NA
NA
NA
NA
NA
NA
The entity is not at a stage where it is in a position to formulate and 
NA
The entity does not have the financial or/human and technical NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Section C) PRINCIPLE WISE PERFORMANCE DISCLOSURE
are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily 
disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically 
responsible.
Principle 1. Businesses should Conduct and Govern themselves with integrity and in a manner that is ethical, transparent 
and accountable. 
Essential Indicators: 
Segment 
Total Number of 
training and awareness 
programmes held 
Topics / principles covered under the 
training and its impact 
% of persons in respective 
category covered by the 
awareness programmes 
Board of Directors 
1
Anti Bribery and Anti Corruption Policy
100%
Key Managerial 
Personnel 
1
Anti Bribery and Anti Corruption Policy
100%
Employees other 
than BoD and KMPs
4
Anti Bribery and Anti Corruption Policy 
POSH Act Grievance Redressal Mechanism 
100%
Not Applicable
2.  
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the 
Balaxi Pharmaceuticals Limited - 
92
Annual Report FY24-25 
10. 
Details of Review of NGRBCs by the Company: 
non-compliances 
working of its policies by an external agency? (Yes/No). If yes, Name of 
12. 
If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated: Questions 
(Yes/No) 
implement the policies on specified principles (Yes/No) 
resources available for the task (Yes/No) 
It is planned to be done in the next financial year (Yes/No) 
Any other reason (please specify) 
This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key 
processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators 
1. 
Percentage coverage by training and awareness programmes on any of the Principles during the financial year: 
Importance of Stakeholders 
Workers 
entity or by directors/ KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the 
following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI 
(Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website): 
A. 
Monetary 
Particulars 
NGRBC 
Principle
Name of the 
regulatory /
Enforcement 
agencies/judicial 
institutions 
Amount (In Rs.)
Brief of the Case
Has an appeal 
been preferred ? 
(Yes/No)
Penalty/Fine
Nil
Exchange 
of 
India applicable GST
During 
the 
year 
under 
review, 
the 
Company 
Regulations,2015, 
due 
to a delay of 27 days in 
appointment 
of 
Woman 
Independent 
Director. 
Consequently, 
the 
Company had paid a fine of 
GST as levied by NSE
No
Settlement 
Nil
Nil
Nil
Nil
Nil
Compounding Fee 
Nil
Nil
Nil
Nil
Nil
B. 
Non Monetary 
Particulars 
NGRBC Principle
Name of the regulatory /
Enforcement agencies/judicial 
institutions 
Brief of the Case
Has an appeal been 
preferred ?  
Yes/No
Imprisonment 
Nil
Nil
Nil
Nil
Punishment 
Nil
Nil
Nil
Nil
3.  
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision are preferred in cases where monetary or 
Case Details 
Name of the regulatory /enforcement agencies/judicial institutions 
Not Applicable
regulations and respects lawful customs of the regions where we operate and transact. We are committed to acting and 
FY 2025
FY 2024
Directors 
Nil
Nil
KMPs
Nil
Nil
Employees 
Nil
Nil
NA
NA
93
Corporate Overview
Statutory Reports
Financial Statements
National 
Stock Rs.1,35,000/- + 
Limited (NSE) 
was 
non-compliant 
with 
Regulation 
17(1) 
(a) 
of 
the 
SEBl(LODR) 
Rs.1,35,000/-+ 
applicable 
non-monetary action has been appealed. 
4. 
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide the details in brief and if available, provide 
a web-link to the policy. 
Yes, Company has an anti - corruption and anti-bribery policy, Company recognises and follows all applicable laws and 
building relationships based on integrity and fairness in all our dealings. Hence, Balaxi has adopted a "Zero Tolerance" 
approach to bribery and corruption. The policy is available on the website of the company at https:/ /balaxipharma.in/ 
corporate-policies. 
5. 
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement 
agency for the charges of bribery/ corruption: 
Workers 
6. 
Details of complaints with regard to conflict of interest
Particulars 
FY 2025
FY 2024
Number
Remarks 
Number
Remarks 
Number of complaints received in relation to issues of Conflict of 
Interest of the Directors
Number of complaints received in relation to issues of Conflict of 
Interest of the KMPs
regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.
 
Not Applicable
FY 2025
FY 2024
Number of days of accounts payables
64
80
Parameter
Metrics
FY 2025
FY 2024
Concentration 
of Purchases
a. 
Purchases from trading houses as % of total purchases
Nil 
Nil 
b. 
Number of trading houses where purchases are made from
Nil 
Nil 
c. 
Purchases from top 10 trading houses as % of total purchases 
from trading houses.
Nil 
Nil 
Concentration 
of Sales
a. 
Sales to dealers /distributors as % of total sales 
Nil 
Nil 
b. 
Number of dealers/ distributors to whom sales are made
Nil 
Nil 
c. 
Sales to top 10 dealers/distributors as % of total sales to 
dealers/distributors 
Nil 
Nil 
Share of RPTS in 
Nil 
Nil 
Nil 
Nil 
Nil 
Nil 
d. 
Investments (Investments in related parties/Total investments 
Nil 
Nil 
Principle 2. Businesses should provide goods and services in a manner that is sustainable and safe.
Essential Indicators:
Category 
Current Financial Year
Previous Financial Year
Details of improvements in 
environmental and social impacts
Nil*
Nil*
Capex 
Nil*
Nil*
Company.
Balaxi Pharmaceuticals Limited - 
94
Annual Report FY24-25 
--
7. 
Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by 
8. 
Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following 
format: 
9. 
Open-ness of business 
Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans 
and advances & investments, with related parties, in the following format 
a. 
Purchases (purchases with related parties/Total purchases) 
·---------------------------------------------------------------------------------------·------------------------------------------------
b. 
Sales (Sales to related parties/Total Sales) 
c. 
Loans and advances(Loans and advances given to related 
parties/Total loans and advances) 
made) 
1. 
Percentage of R&D and capital expenditure (CAPEX) investments in specific technologies to improve the environmental 
and social impacts of product and processes to total R&D and capex investments made by the entity, respectively. 
R&D 
*As on March 31,2025, the Company is operating on an asset -light model and hence, no capex has been incurred by the 
In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for 
such disclosures. 
2. 
Sustainable Sourcing 
 
If yes, what percentage of inputs were sourced sustainably? 
3. 
Describe the processes in place to reclaim products for reusing, recycling, and disposing at the end of life for
 
We ensure that the products are disposed off/reused/recycled, as per the nature of the product at the end of the life 
 
Not applicable. Company is not involved in any manufacturing activity. The Company is engaged in the business of 
PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value 
chains
1.
Category
% of employees covered by
Total 
A
Health Insurance
Accident 
insurance
Maternity 
Benefits
Paternity 
Benefits
Day Care 
Facilities
Number 
B
% 
(B/A)
Number 
C
%
Number 
D
% 
(D/A)
Number 
E
% 
(E/A)
Number 
F
% 
(F/A)
Permanent Employees
Male
0
23
100
23
100
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
Other than permanent employees
Male
0
0
0
0
0
0
0
0
0
0
0
Female 
0
0
0
0
0
0
0
0
0
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for 
such disclosures.
95
Corporate Overview
Statutory Reports
Financial Statements
a. 
Does the entity have procedures in place for sustainable sourcing? (Yes/No) 
Yes, we have GMP-certified Contract Development Manufacturing Organizations 
a. 
Plastics ( Including Packaging) :Yes 
b. 
E-Waste:Yes 
c. 
Hazardous waste: Yes 
d. 
other waste :Yes 
cycle in respective markets. 
4. 
Extended Producer Responsibility (EPR) 
Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the 
waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control 
Boards? If not, steps taken to address the same. 
International Wholesale Distribution in various international markets. 
a. 
Details of measures for the well-being of employees 
(CIA) 
Category
% of workers covered by
Total 
A
Health Insurance
Accident 
insurance
Maternity 
Benefits
Paternity 
Benefits
Day Care 
Facilities
Number 
B
% 
(B/A)
Number 
C
%
Number 
D
% 
(D/A)
Number 
E
% 
(E/A)
Number 
F
% 
(F/A)
Permanent workers
Male
0
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
Other than permanent workers 
Male
0
0
0
0
0
0
0
0
0
0
0
Female 
0
0
0
0
0
0
0
0
0
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for 
such disclosures. 
FY 2025 
Current Financial Year
FY 2024 
Previous Financial Year
company
Nil 
Nil 
2.  
Details of retirement benefits, for current FY and previous financial year 
Benefits 
FY 2025
FY 2024
Number of 
employees 
covered as 
% of total 
employees 
Number of 
Workers 
covered as 
% of total 
employees
Deducted and 
deposited with 
the authority 
(Y/N/N.A)
Number of 
employees 
covered as 
% of total 
employees 
Number of 
Workers 
covered as 
% of total 
employees
Deducted and 
deposited with 
the authority 
(Y/N/N.A)
PF
100%
NA
Yes
100%
NA
Yes
Gratuity 
100%
NA
Yes
100%
NA
Yes
ESI
16.66%
NA
Yes
17.65%
NA
Yes
 
Yes, the office of the Company is accessible to differently abled employees.
4. 
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide 
Gender 
Permanent Employees 
Permanent Workers 
Return to work Rate 
Retention Rate
Return to work Rate 
Retention rate 
Male 
NA
NA
NA
NA
Female 
Total 
NA
NA
NA
NA
Balaxi Pharmaceuticals Limited - 
96
Annual Report FY24-25 
b. 
Details of measures for the well-being of Workers 
(CIA) 
c. 
Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in 
the following format -
Cost incurred on well-being measures as a % of total revenue of the 
Others - specify 
3. 
Accessibility of workplaces 
Are the premises/ offices of the entity accessible to differently abled employees and workers, as per the requirements of 
the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard. 
a web-link to the policy. 
Yes, the policy is available on the website of the company at https://balaxipharma.in/corporate-policies. 
5. 
Return to work and Retention rates of permanent employees and workers that took parental leave. 
If yes, give details of the mechanism in brief.
Particulars 
Yes/No ( if yes then give details of the mechanism in brief ) 
Not Applicable
Not Applicable
Permanent Employees 
Yes, 
orientation, religion, marital status and social class
2. 
Violation of human rights
4. 
Denial of applicable benefits,
Other than permanent Employees 
Not Applicable
Category
FY 2025
FY 2024
Total 
employees/
workers in 
respective 
category (A)
Total employees/
workers in respective 
category, who are part 
of association (s) or 
Union (s)
% B/A
Total 
employees/
workers in 
respective 
category (A)
Total employees/
workers in respective 
category, who are part 
of association (s) or 
Union (s)
% B/A
Total Permanent Employees 
Male
0
0
0
0
0
0
Female
0
0
0
0
0
0
Male
NA
NA
NA
NA
NA
NA
Female
NA
NA
NA
NA
NA
NA
Category
FY 2025
FY 2024
Total 
(A)
On health and 
safety Measures
On skill 
upgradation
Total
On health and 
safety Measures
On skill upgradation
NO. B
% (B/A)
No.C
% (C/A)
(D)
No. (E)
% (E/D)
No.(F)
%(F/D)
Employees
Male
23
23
100
23
100
37
37
100
37
100
Female 
0
0
0
0
0
9
9
100
9
100
Total 
23
23
100
23
100
46
46
100
46
100
Male
 NA
NA
 NA
NA
 NA
NA
 NA
NA
 NA
NA
Female
 NA
NA
 NA
NA
 NA
NA
 NA
NA
 NA
NA
Total 
 NA
NA
 NA
NA
 NA
NA
 NA
NA
 NA
NA
97
Corporate Overview
Statutory Reports
Financial Statements
6. 
Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? 
Permanent Workers 
Other than Permanent Workers 
The Company has a Grievance Redressal policy, which address all kinds of issues 
an employee may face while at work. The grievance may include: 
1. 
Any kind of discrimination on account of disability, gender, race, sexual 
3. 
Bullying/ workplace harassment 
5. 
Working conditions 
7. 
Membership of employees and worker in association(s) or Unions recognised by the listed entity: 
Total Permanent Workers 
8. 
Details of Training imparted to the employees and workers on health & safety measures and on skill upgradation 
----
Workers 
Category
FY 2025
FY 2024
Total (A)
No.(B)
% (B/A)
Total C
No.(D)
% (D/C)
Employees
Male
23
23
100
37
37
100
Female
0
0
0
9
9
100
Total 
23
23
100
46
46
100
Male
 NA
NA
 NA
NA
 NA
NA
Female
 NA
NA
 NA
NA
 NA
NA
Total
 NA
NA
 NA
NA
 NA
NA
10. 
Health and safety management system
a. 
Whether an occupational health and safety management system has been implemented by the entity? 
If 
yes, the coverage such system? 
 
Yes, the company has implemented the Health and Safety Policy which covers all the employees of the Company.
by the entity? 
 
Yes 
 
Yes 
11. 
Details of safety related incidents 
Safety Incident / Number 
Category 
FY 2025
FY 2024
Employees
0
0
NA
NA
Employees
0
0
NA
NA
No of fatalities 
Employees
0
0
NA
NA
Employees
0
0
NA
NA
•  
Women safety programs
•  
Road safety programs
•  
Fire emergency training exit
Balaxi Pharmaceuticals Limited - 
98
Annual Report FY24-25 
9. 
Details of performance and career development reviews of employees and workers: 
Workers 
(Yes/No). 
b. 
What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis 
Appropriate policies / guidelines have been formulated to address various types of hazards and related risk 
assessment & mitigation. 
All work-related hazards are identified basis the recommended guidelines. 
Their associated risk assessment procedures are part of the Safety manual. 
c. 
Whether you have processes for workers to report the work-related hazards and to remove themselves from such 
risks. (Y /N) 
d. 
Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ 
No) 
Lost Time Injury Frequency Rate (LTIFR) Per One million 
-person hours worked 
Total recordable work-related injuries 
High consequence work-related injury or ill-health (excluding 
fatalities) 
Workers 
Workers 
Workers 
Workers 
12. 
Describer the measures taken by the entity to ensure a safe and healthy work-place. 
Employee well-being programs/initiatives are conducted for all the employees and during FY 2024-25 the following well-
being initiatives were undertaken: 
• 
Posh &amp; gender sensitization meetings 
• 
Women self-defense program 
• 
General health check up 
FY 2025
FY 2024
Filed during 
the year 
Pending 
resolutions at the 
end of the year 
Remarks 
Filed during 
the year 
Pending 
resolutions at the 
end of the year 
Remarks 
14. 
Assessments for the year 
Particulars 
% of plants and offices that were assessed  
(By entity or statutory authorities or third parties 
Health and safety practices 
100%
100%
Further, Training of all employees regarding protocol to be followed in case of any safety incident has been conducted 
Principle 4. Businesses should respect the interests of and be responsive to all its stakeholders.
Essential Indicators:
1. 
understanding their needs and expectations accordingly. The WHO GMP certified units from which Balaxi procures 
2. 
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Other
Frequency of 
engagement 
(Annually/ Half yearly/ 
Quarterly / others – 
please specify)
Purpose and scope of 
engagement including 
key topics and 
concerns raised during 
such engagement
Customers 
(Distributors, 
Wholesalers 
No
social media, Calls.
It is a continuous 
process
Addressing 
requirements 
for products and 
grievances, if any
Suppliers/
CDMOs
No
online and offline meetings, 
Daily
To share the specific 
requirements, Status 
update on product 
deliveries and other 
terms of trade.
99
Corporate Overview
Statutory Reports
Financial Statements
13. 
Number of complaints made by employees and workers 
Working Conditions 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
·--------------------------------------------------·-------------------------------------------------------------------------------------------------------------
Hea Ith & Safety 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
Working Conditions 
15. 
Details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / 
concerns arising from assessments of health & safety practices and working conditions. 
The Company has implemented Hygiene Policy which ensures workplace cleanliness and basic amenities like availability 
of clean drinking water, proper sanitation facilities, etc. 
The HR team conducts review on a quarterly basis to ensure all the points under the hygiene policy are taken care of. 
Describe the process for identification of key stakeholder groups of the entity. 
Balaxi, a pharmaceutical distribution company, effectively identifies its stakeholders through meticulous research and 
analysis. Senior management and HODs of the respective departments interact with the respective stakeholders before 
forming an association. Primary stakeholders such as customers, suppliers, employees, and investors are recognized, 
products are also considered stakeholders, ensuring high-quality standards. 
List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group. 
and Retailers) 
-
satisfaction surveys 
Marketing and advertising 
-
Complaint 
handling 
and 
feedback 
Electronic communication 
-
Regular 
interaction 
through 
phone calls, e-mails 
-
Conferences and workshops 
In Person Meetings/ Visits. 
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Other
Frequency of 
engagement 
(Annually/ Half yearly/ 
Quarterly / others – 
please specify)
Purpose and scope of 
engagement including 
key topics and 
concerns raised during 
such engagement
Employees
No
programmes
system.
publications
initiatives.
For smooth functioning 
of business operations.
Investors
No
conference calls. 
meets.
Results and newsletters.
Quarterly/Annually/ 
Need basis
To provide updates on 
company’s operations 
and Financial 
Performance
Government/
regulators
No
Business and 
compliance related
Community
Yes
towards various causes
CSR Initiatives of the 
Company
Principle 5. Businesses should respect and promote human rights.
Essential Indicators 
Category 
FY 2025 Current financial Year
FY 2024 Previous Financial Year
Total 
(A)
Number of 
employees and 
workers covered (B)
% (B/A)
Total (C)
Number of 
employees and 
workers covered (D)
% (D/C)
Employees
Permanent 
48
48
100
46
46
100
Other than Permanent 
0
0
0
46
46
100
Total Employees 
48
48
100
46
46
100
Workers
Permanent 
Other than permanent 
Balaxi Pharmaceuticals Limited - 
100
Annual Report FY24-25 
-
Trainings 
and 
development Daily/ Weekly 
Performance 
management 
Emails. Written communication 
circulars 
and 
internal 
Employee 
engagement 
-
Annual General meeting 
Investor 
presentations 
and 
Investor 
conferences 
and 
Press 
releases, 
Quarterly 
Meetings and formal dialogue 
Others - Need Basis 
Filings with the regulators. 
·----------------------·------------------------·----------------------------------------------·--------------------------------·--------------------------------· 
CSR partnerships - Contribution 
Others- Need basis 
1. 
Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the 
following format: 
Total Workers 
Category 
FY 2025
FY 2024
Total 
(A)
Equal to 
Minimum Wage 
More than 
Minimum Wage
Total 
(D)
Equal Minimum 
Wage
More than 
minimum wage
No.(B)
%(B/A)
No.(C)
% (C/A)
No. (E)
% (E/D)
No.(F)
% (F/D)
Employees
Permanent 
Male
43
0
0
43
100
37
0
0
37
100
Female 
5
0
0
5
100
9
0
0
9
100
Other than Permanent 
Male
Female
Workers
Permanent 
Male
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Female 
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Other than Permanent 
Male
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Female
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Category 
Male 
Female 
Number 
Median remuneration/
salary/wages of respective 
category (Rs.in Lakhs)
Number 
Median remuneration/
salary/wages of respective 
category (Rs.in Lakhs)
Board of Directors 
4
2.5
2
1.75
Key Managerial Personal 
4
40.00
-
-
Employees other than BoD and KMP
43
4.78
5
1.8
Workers 
-
-
-
-
FY 2024 Previous Financial Year
FY 2024 Previous Financial Year
Gross wages paid to females as % of total wages
 
Yes
5.  
Describe the internal mechanisms in place to redress grievances related to human rights issues. 
comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, 
sensitivity, while delivering timely action and closure.
101
Corporate Overview
Statutory Reports
Financial Statements
2. 
Details of minimum wages paid to employees and workers, in the following format 
3. 
Details of remuneration/ salary/ wages (including differently abled) 
1. 
Gross wages paid to females as % of total wages paid by the entity, in the following format: 
4. 
Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or 
contributed to by the business? (Yes/No) 
Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization 
has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or 
concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism 
confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with 
Category 
FY 2025 Current financial Year
FY 2024 Previous Financial Year
Filed 
during 
the day 
Pending 
Resolution at the 
end of the year 
Remarks 
Filed 
During 
the Year 
Pending 
Resolution at the 
end of the year 
Remarks 
Sexual Harassment 
Wages
Other human right related issues 
FY 2025
FY 2024
Complaints on POSH as a % of 
Complaints on POSH upheld
8. 
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases. 
comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, 
sensitivity, while delivering timely action and closure.
10. 
Assessments of the year
Category 
% of plants and offices that were assessed (by the entity or 
by the statutory authorities or third parties)
100%
100%
Sexual harassment 
100%
100%
Wages 
100%
NA
assessments at Question 9 above.
Balaxi Pharmaceuticals Limited - 
102
Annual Report FY24-25 
6. 
Disclosure of complaints made by employees and workers on sexual harassment, discrimination at workplace, Child 
Labour, Forced Labour/Involuntary Labour, Wages or other human rights related issues.: NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
Discrimination at workplace 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
·--------------------------------------------------------------·-------------------------·---------------·--------------·----------------------------------------· 
Forced Labour/Involuntary Labour 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
7. 
Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 
2013, in the following format:NIL 
Total Complaints reported under Sexual Harassment on of Women at Workplace 
(Prevention, Prohibition and Redressal) Act, 2013 (POSH) 
female employees/ workers 
NIL 
NIL 
NIL 
NIL 
NIL 
NIL 
Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization 
has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or 
concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism 
confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with 
9. 
Do human rights requirements form part of your business agreements and contracts? (Yes/No): Yes 
Child Labour 
Forced/Involuntary Labour 
Discrimination at workplace 
Others - please specify 
11. 
Provide the details of any corrective actions taken or underway to address significant risks/ concerns arising from the 
No significant risks reported in the assessment. 
Principle 6. Businesses should respect and make efforts to protect and restore the environment. 
Essential Indicators:
Parameter 
FY 2025  
(in Giga Joules)
FY 2024  
(in Giga Joules)
From renewable sources
Nil
133.81
Nil
Nil
Nil
Nil
Total energy consumed from renewable resources (A+B+C) 
Nil
Nil
From non-renewable sources
113.86
133.81
Nil
Nil
Nil
Nil
Nil
Nil
Total energy consumed from non-renewable resources (D+E+F)
Nil
Nil
Total energy consumed. (A+B+C+D+E+F)
113.86
133.81
Energy intensity per rupee of turnover 
0.011GJ/Rs.Lakhs
Energy intensity per rupee of turnover adjusted for Purchasing Power 
Parity (PPP)
NA
NA
Energy intensity in terms of physical output
NA
NA
Energy intensity 
NA
NA
name of the external agency.
 
No
3. 
Provide details of the following disclosures related to water, in the following format
Parameter 
FY 2025
FY 2024
NA
NA
1,388
967
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
1388
967
1388
967
Water intensity per rupee of turnover (Water consumed / Revenue from 
Water intensity per rupee of turnover adjusted for Purchasing Power Parity 
NA
NA
Water intensity in terms of physical output
NA
NA
NA
NA
name of the external agency
103
Corporate Overview
Statutory Reports
Financial Statements
1. 
Details of total energy consumption (in Joules or multiples) and energy intensity 
Total electricity consumption (A) 
Total fuel consumption (B) 
Energy consumption through other sources (C) 
Total electricity consumption (D) 
Total fuel consumption (E) 
Energy consumption through other sources (F) 
(Total energy consumption/ turnover in rupees) 
(Total energy consumed / Revenue from operations adjusted for PPP) 
(optional)- the relevant metric may be selected by the entity 
0.013 GJ/Rs.Lakhs 
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
2. 
Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and 
Trade (PAT) Scheme of the Government of India? (Y /N). If yes, disclose whether targets set under the PAT scheme have 
been achieved. In case targets have not been achieved, the remedial action taken, if any. 
Water Withdrawal by Source ( In Kiloliters) 
(i) Surface water 
(ii) Groundwater 
(iii) Third party water 
(iv) Seawater/ desalinated water 
(v) Others 
Total volume of water consumption (in kilolitres) 
operations) 
(PPP) 
(Total water consumption / Revenue from operations adjusted for PPP) 
Water intensity (optional) - the relevant metric may be selected by the entity 
0.14/KI/Rs.Lakhs 
0.09 /KI/Rs.Lakhs 
Note - Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) . If yes, 
Parameter
FY 2025 
(Current Financial Year)
FY 2024 
(Previous Financial Year)
Nil 
(i)  
To Surface water
(ii)  
To Groundwater
(iii)  To Seawater
(iv)  Sent to third-parties
(v)  
Others
Total water discharged (in kilolitres)
name of the external agency.
implementation.
not own any manufacturing plants.
Parameter
Please specify unit 
FY 2025
FY 2024
NOx
Nil
Nil
Sox
Nil
Nil
Particulate Mater 
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
The Company is not into manufacturing and therefore the possibility of releasing emissions into the atmosphere is negligible/
not applicable
name of the external agency
No
Balaxi Pharmaceuticals Limited - 
104
Annual Report FY24-25 
4. 
Provide the following details related to water discharge -
Water discharge by destination and level of treatment (in kilolitres) 
- No treatment 
- With treatment - please specify level of treatment 
- No treatment 
- With treatment - please specify level of treatment 
- No treatment 
- With treatment - please specify level of treatment 
- No treatment 
- With treatment - please specify level of treatment 
- No treatment 
- With treatment - please specify level of treatment 
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
5. 
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
Zero Liquid Discharge is not applicable to the Company as it is an International Wholesale Distribution Company and does 
6. 
Please provide the details of air emissions (other than GHG emissions) by the entity, in the following format -
Persistent organic pollutants (POP) 
Volatile organic compounds (VOC) 
Hazardous air pollutants (HAP) 
Others - please specify 
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
Parameter 
Unit
FY 2025
FY 2024
Total Scope 1 emissions 
Metric tonnes 
of CO2 
equivalent
Nil 
Nil
Total Scope 2 emissions 
Metric tonnes 
of CO2 
equivalent
25.30 tCO2e
Total Scope 1 and Scope 2 emissions intensity per rupee of turnover 
(Total Scope 1 and Scope 2 GHG emissions / Revenue 
-
-
Total Scope 1 and Scope 2 emission intensity per rupee of turnover 
adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 
-
-
Total Scope 1 and Scope 2 emission intensity in terms of physical 
output
-
-
Total Scope 1 and Scope 2 emission intensity 
relevant metric may be selected by the entity 
-
-
The Company is not into manufacturing and therefore the possibility of releasing greenhouse gas emissions into the atmosphere 
is negligible/not applicable.
name of the external agency
No
8. 
Does the entity have any project related to reducing Green House Gas emission? If yes, then provide the details.
 
No
9. 
Provide details related to waste management by entity , in the following format 
Parameter 
FY 2025
FY 2024
Total Waste generated (in metric tonnes)
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Nil
Other Hazardous waste (G). Please specify if any 
Nil
Nil
 
Nil
Nil
Total ( A+B+C+D+E+F+Gg+H)
Nil
Nil
Waste intensity per rupee of Turnover (Total waste generated / Revenue from 
operations)
Nil
Nil
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP)(Total waste generated / Revenue from operations adjusted for PPP)
Nil
Nil
Waste intensity in terms of physical output
Nil
Nil
Waste intensity (optional) – the relevant metric may be selected by the entity
Nil
Nil
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations 
(in metric tonnes) 
105
Corporate Overview
Statutory Reports
Financial Statements
7. 
Please provide the details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & their intensity 
(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if 
available) 
(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if 
available) 
from operations) 
2 GHG emissions/ Revenue from operations adjusted for PPP) 
(optional) - the 
-
29.75 tCO,e 
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
Plastic waste ( A) 
·---------------------------------------------------------------------------------------------------------------------------------------------------------------
E-waste ( B) 
Bio-medical waste ( C) 
Construction and demolition waste (D) 
·---------------------------------------------------------------------------------------------------------------------------------------------------------------
Battery waste (E) 
Radioactive waste (F) 
Other Non-hazardous waste generated (H) 
(Break-up by composition i.e by materials relevant to the sector 
Parameter 
FY 2025
FY 2024
Category of waste 
Nil
Nil
Nil
Nil
iii.Other recovery operations 
Nil
Nil
Total 
Nil
Nil
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes) 
Category of Waste 
i.Incineration
Nil
Nil
Nil
Nil
iii.Other disposal operations 
Nil
Nil
Total 
Nil
Nil
The nature of business of the Company is International Wholesale Distribution where the Company does not have any 
manufacturing facility or produce anything inhouse and hence, this clause is not applicable.
name of the external agency
No
10. 
Briefly describe the details of waste management practices adopted in your establishments. Describe the strategy adopted 
by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices 
adopted to manage such wastes.
 
As an International Wholesale Distribution Company, we do not manufacture any products and thus do not use any 
hazardous or toxic chemicals.
/ clearances are required, 
S. No.
Location of 
operations/offices 
Type of operations 
Whether the conditions of environmental approval / clearance 
are being complied with? (Y/N) 
If no, the reasons thereof and corrective action taken, if any. 
Not Applicable
 
During the reporting period, the Company has not conducted any environment impact assessment. Company ensures 
compliance to local and national laws wherever required.
Name and brief 
details of project 
EIA 
Notification 
No.
Date
Whether conducted by 
independent external 
agency (Yes / No) 
Results communicated 
in public domain 
(Yes / No) 
Relevant Web 
Link 
Not Applicable
13. 
Is the entity compliant with the applicable environmental law/ regulations/ guidelines inIndia, such as the Water 
 
Yes
SL 
No
Specify the Law / regulation 
/ guidelines which was not 
complied with 
Provide details 
of the non-
compliance 
Any fines / penalties / action taken by 
regulatory agencies such as pollution 
control boards or by courts
Corrective action 
taken, if any 
Not applicable
Balaxi Pharmaceuticals Limited - 
106
i.Re-cycled 
ii.Re-used 
ii.Landfilling 
Annual Report FY24-25 
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N). If yes, 
11. 
If the entity has operations/offices if any in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, 
biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals 
12. 
Details of environmental impact assessments (EIA) of projects undertaken by the entity based on applicable laws, in the 
current financial year: 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and 
rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format: 
Principle 7. Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible 
and transparent.
Essential Indicators 
1 a. Number of affiliations with trade and industry chambers/associations. 5
entity is a member of /affiliated to 
SL 
No
Name of the trade industry chambers/associations 
The reach of trade and industry 
chambers/associations (State/National)
1
Two Star Export House Certificate by Directorate General of Foreign 
trade
National
2
Pharmexcil Registration from Pharmaceuticals Export Promotion Council 
of India
National
3
FSSAI Certification from Food Safety and Standards Authority of India 
National
4
Certification from Agricultural and Processed Food Products Export 
National
5
National
based on adverse orders from regular authorities.
Name of authority 
Brief of the case 
Corrective actions taken 
Principle 8. Businesses should promote inclusive growth and equitable development 
Essential Indicators
financial year.
Name and brief 
details of the 
project
SIA 
notification 
No.
Date of 
notification 
Whether conducted by 
an Independent external 
agency (Yes/No) 
Results communicated 
in public domain (Yes/ 
No) 
Relevant 
weblink 
Not Applicable
SL No
Name of project 
for which R&R is 
ongoing 
State 
District 
No. of project-affected 
families 
% of PAFs 
covered by 
R&R
Amount paid 
to PAFs in 
FY(In INR)
Not Applicable
3. 
Describe the mechanisms to receive and redress grievances of the community
Particulars 
FY 2025
FY 2024
Directly sourced from MSMEs/small producers
96.04%
95.05%
Directly from within India
107
Corporate Overview
Statutory Reports
Financial Statements
b. 
List the top 10 trade and industry chambers/associations ( determined based on the total members of such body ) the 
(FSSAI) 
Development Authority (APEDA) 
Member of Federation of Indian Export Organisation (FIEO) 
2. 
Provide Details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, 
NIL 
1. 
Details of social impact assessments ( SIA) of projects undertaken by the entity based on applicable laws, in the current 
2. 
Information on project (s) for which ongoing rehabilitation and resettlement ( R&R) is being undertaken by the entity, in 
the following format -
We have a grievance redressal mechanism which covers all our stakeholders. Active engagement with the community 
and stakeholders requires an effective grievance redressal system that includes feedback loops and conflict resolution 
mechanisms. Stakeholders can share their feedback/ concern on info@balaxipharma.in 
4. 
Percentage of input material (inputs to total inputs by value) sourced from suppliers 
Location
FY 2025 
(Current Financial Year)
FY 2024 
(Previous Financial Year)
Rural
Nil 
Urban
Metropolitan
Principle 9. Businesses should engage with and provide value to their consumers in a responsible manner.
Essential Indicators
 
Consumers can directly contact the Company through email or phone and further our representative visits all the clients 
2. 
Turnover of products and /services as a percentage of turnover from all products/service that carry information about 
Particulars 
As a % of total turnover 
Environmental and social parameters relevant to the product 
100
Safe and responsible usage 
100
Recycling and/or safe disposal 
100
3. 
Number of consumer complaints in respect of the following 
Particulars 
FY 2025
Remarks
FY 2024
Remarks 
Received 
during the 
year 
Pending 
resolution at 
end of year
Received 
during the 
year 
Pending 
resolution at 
end of year
Data Privacy
0
0
0
0
Advertising
0
0
0
0
0
0
0
0
Delivery of essential services 
0
0
0
0
Restrictive Trade Practices 
0
0
0
0
Unfair Trade Practices 
0
0
0
0
Other 
0
0
0
0
Particulars 
Number 
Reasons for recall 
Voluntary recalls 
0
N.A
Forced recalls 
0
N.A
(Yes/No) 
Balaxi Pharmaceuticals Limited - 
108
Annual Report FY24-25 
2. 
Job creation in smaller towns - Disclose wages paid to persons employed (including employees or workers employed on 
a permanent or non-permanent/ on contract basis) in the following locations, as % of total wage cost 
Semi-Urban 
1. 
Describe the mechanism in place to receive and respond to consumer complaints and feedback 
regularly for their feedback and issues, if any. 
Cyber-security 
4. 
Details of instances of product recalls on account of safety issues: 
5. 
Does the entity have Framework/ policy on cyber security and risks related to data privacy? 
link of the policy. 
Yes, the policy is available at https://balaxipharma.in/corporate-policies. 
If available, web-
3. 
Provide Details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential 
services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action 
taken by regulatory authorities on safety of products / services. :None 
4. 
Provide the following information relating to data breaches: 
a. 
Number of instances of data breaches : None 
b. 
Percentage of data breaches involving personally identifiable information of customers: None 
c. 
Impact, if any, of the data breaches:None 
